Antigenics logo

Antigenics(OTC) ANTI

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)-100%
5 Year-100%
1 Year-98%
1 Month+100%
N/A
Antigenics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-05-14
Antigenics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+100%USD 0.002025-05-16
1 month+100%USD 0.002025-05-16
3 month+100%USD 0.002025-05-16
Year to date+100%USD 0.002025-05-16
1 year-98%USD 0.002024-12-12
3 year+100%USD 0.002023-05-08
5 year-99.97%USD 0.012021-05-12
Since inception-100%USD 0.051996-02-15

Antigenics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

ANTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Antigenics

Antigenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, manufacturing, and developing immunotherapies for cancer. Founded in 1994 and based in Lexington, Massachusetts, the company aims to innovate in the biotechnology sector.

Products and Services
  • Immunotherapy treatments targeting various cancer types
  • Research and development of novel therapeutic agents
  • Collaboration with research institutions for advanced cancer therapies
Growth Outlook
  • Potential for significant market expansion in cancer immunotherapy
  • Increasing demand for innovative cancer treatments globally
  • Strategic partnerships may enhance research capabilities and product pipeline
Financial Highlights
  • Recent stock price range between 0.000007 and 0.00001
  • Volume of shares traded recently reached 3,000
  • Market capitalization remains at zero, indicating early-stage development
Antigenics, Inc. operates in a highly competitive biotechnology landscape, focusing on cancer immunotherapy, which is a rapidly growing field. The company's commitment to innovation and collaboration positions it well for future growth. Despite the current market capitalization being zero, the potential for strategic partnerships and advancements in cancer treatment could lead to significant opportunities. The recent trading volume indicates interest, and the stock price reflects the early-stage nature of the company. Investors may find the developments in Antigenics noteworthy as the company continues to navigate the complexities of the biopharmaceutical industry.
AI Generated • Sep 25, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Lexington, MA 02421-7305, US

ANTI Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Antigenics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About ANTI

What is the current price of Antigenics?

Antigenics is trading at N/A per share.

What is the 52-week range for Antigenics?

Over the past 52 weeks, Antigenics has traded between N/A and N/A.

How much debt does Antigenics have?

Antigenics total debt is unavailable.

How much cash does Antigenics have on hand?

Antigenics does not have cash on hand data available.

What is Antigenics’s dividend yield?

Antigenics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services